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ABSTRACT 
In vertebrates, early brain development takes place at the expanded anterior end of the neural tube. After 
closure of the anterior neuropore, the brain wall forms a physiologically sealed cavity that encloses embryonic 
cerebrospinal fluid (E-CSF), a complex and protein-rich fluid that is initially composed of trapped amniotic fluid. 
E-CSF has several crucial roles in brain anlagen development. Recently, we reported the presence of transient 
blood–CSF barrier located in the brain stem lateral to the ventral midline, at the mesencephalon and 
prosencephalon level, in chick and rat embryos by transporting proteins, water, ions and glucose in a selective 
manner via transcellular routes. To test the actual relevance of the control of E-CSF composition and 
homeostasis on early brain development by this embryonic blood-CSF barrier, we block the activity of this 
barrier by treating the embryos with 6-aminonicotinamide gliotoxin (6-AN). We demonstrate that 6-AN 
treatment in chick embryos blocks protein transport across the embryonic blood-CSF barrier, and that the 
disruption of the barrier properties is due to the cease transcellular caveolae transport, as detected by CAV-1 
expression cease. We also show that the lack of protein transport across the embryonic blood-CSF barrier 
influences neuroepithelial cell survival, proliferation and neurogenesis, as monitored by neurepithelial 
progenitor cells survival, proliferation and neurogenesis.  The blockage of embryonic blood-CSF transport also 
disrupts water influx to the E-CSF, as revealed by an abnormal increase in brain anlagen volume. These 
experiments contribute to delineate the actual extent of this blood-CSF embryonic barrier controlling E-CSF 
composition and homeostasis and the actual important of this control for early brain development, as well as to 
elucidate the mechanism by which proteins and water are transported thought transcellular routes across the 
neuroectoderm, reinforcing the crucial role of E-CSF for brain development. 
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INTRODUCTION 
 In vertebrates, early brain development 
takes place at the expanded anterior end of the 
neural tube. After closure of the anterior 
neuropore, brain walls form a large and 
physiologically sealed cavity enclosing embryonic 
cerebrospinal fluid (E-CSF), a complex and protein-
rich fluid. Chick and rat E-CSF proteomes analyzed 
at embryological stage E4 (E is for days of 
incubation) or HH23 (according to Hamburger and 
Hamilton, 1951) [1] and at E12.7 respectively 
include molecules whose roles explain the general 
functions reported for this fluid [2-5]. Thus, E-CSF is 
involved in several crucial roles in brain anlagen 
growth and development: (1) it exerts positive 
pressure against the neuroepithelial walls and 
generates an expansive force [6-11]; (2) it 
contributes to regulate the survival, proliferation 
and neurogenesis of neuroectodermal stem cells 
[12]; and (3) it collaborates with a well-known 
organising centre, the mesencephalic-
metencephalic boundary or midbrain-hindbrain 
isthmus (IsO), to regulate neuroepithelial gene 
expression patterning [13]. 
 The microenvironment of the CNS is 
important for neuronal development and function, 
including E-CSF composition and homeostasis. The 
existence of a transient blood-CSF barrier located 
at the brain stem lateral to the ventral midline, at 
the mesencephalon and prosencephalon level, 
between embryonic days E3 and E5 in chick 
embryos have been identified [14]. This blood-CSF 
barrier, which may operate in rat embryos at en 
equivalent brain developmental stages, i.e. at 
E12.7-E13.7, as suggested by the presence of the 
same specific transporters [15, 16], is formed by 
specific blood vessels immersed in the mesoderm 
and the neuroectoderm close to them, and controls 
E-CSF composition and homeostasis during this 
early stages of brain development, before the 
formation of functional choroids plexuses –the 
organs fulfilling blood-CSF barrier function in later 
foetuses and adults. 
 It has been demonstrated that this 
embryonic blood-CSF barrier transports proteins in 
a selective manner through transcellular routes 
[14], most probably by means of caveolae as 
detected by the presence of CAV-1 in both blood 
vessels and the neuroectoderm conforming the 
embryonic blood-CSF barrier [16]; water and ions 
through specific transporters, identified by the 
presence of aquaporins 1 & 4  (AQP1 and AQPO4) 
and inwardly rectifying K+ channel (Kir4.1) in the 
blood vessels but not in the neuroectoderm [15]; 
and glucose, by means of GLUT-1 transporter, 
detected in both blood vessels and the 
neuroectoderm conforming the embryonic blood-
CSF barrier [16].  
 However, the actual relevance of the control 
of E-CSF composition and homeostasis on early 
brain development exerted by this embryonic 
blood-CSF barrier has not been experimentally 
tested. To achieve this objective, we blocked the 
activity of the embryonic blood-CSF barrier by 
treating the embryos with a specific toxin, namely 
6-aminonicotinamide gliotoxin (6-AN), a known 
antimetabolite of nicotinamide [17-20]. Despite 6-
AN is a commonly used gliotoxic substance exerting 
a known inhibitory effect on the pentose 
phosphate shunt and a secondary effect on the 
direct glycolytic pathway [21, 22], several in vivo 
investigations including ultrastructural analysis of 
the endothelial cell tightness and vascular 
permeability monitoring have shown that it also 
breaks-down the integrity of the BBB [20, 22-26]. In 
this respect, it is important to highlight that we did 
use this substance only as a tool for its BBB 
blockage properties, irrespective of its other 
features. 
 Here we demonstrate that when chick 
embryos are treated with 6-AN, protein transport 
across the embryonic blood-CSF barrier blocks for 
both endogenous and exogenously microinjected 
proteins, and that the disruption of the barrier 
properties is due to the cease of CAV-1 expression, 
thus linking protein transport to caveolae-mediated 
transcellular transport. We also show that the lack 
of protein transport across the embryonic blood-
CSF barrier influences neuroepithelial cell survival, 
proliferation and neurogenesis. Moreover, the 
blockage of embryonic blood-CSF transport also 
disrupts water influx to the E-CSF, as revealed by an 
abnormal increase in brain anlagen volume, also 
linking water transport to caveolae-mediated 
transcellular transport across the neuroectoderm. 
Taken together, these results contribute (1) to 
delineate the actual extent of the blood-CSF 
embryonic barrier controlling E-CSF composition 
and homeostasis, (2) to check the importance of 
this control for early brain development, and (3) to 
elucidate the mechanism by which proteins and 
water are transported thought transcellular routes 
across the neuroectoderm, reinforcing the crucial 
Open Journal of Neuroscience, 2011, 1-3       6-AN disrupts embryonic blood-CSF barrier
         
Page 3 of 11 
 (Page number not for citation purposes) 
 
role of E-CSF for brain development. 
MATERIAL AND METHODS 
Obtaining chick embryos 
 Fertile chicken eggs (Gallus gallus; White-
Leghorn strain) were incubated at 38 °C in a 
humidified atmosphere to obtain embryos at the 
desired developmental stage, i.e. at E3 (HH20), E4 
(HH23), E5 (HH26) and E6 (HH29) (E stands for 
embryonic day from the beginning of incubation; 
HH stands for the Hamburger and Hamilton [1951] 
[1] developmental stages, as described in Bellairs 
and Osmond, 2005) [27]. Local and European 
guidelines for animal research were followed (CEEA 
– Comitè Ètic d’Experimentació Animal -Ethical 
Committee for Animal Experimentation- code 
number: DMAiH 3777). 
Microinjection of molecules  
 Microinjection of the several different 
molecules used in this study was performed in ovo 
with a glass microneedle (30 μm inner diameter at 
the tip) connected to a microinjector (Nanoject II) 
through a small opening made in the 
extraembryonic membranes with a sterilised 
tungsten needle. Molecules were microinjected 
into the mesencephalic cavity (10 pulses of 23 nl 
each) to monitor E-CSF/E-serum transfer, as this is 
the largest cavity in the avian brain at this stage of 
development. Alternatively, they were injected into 
the outflow tract of the heart (10 pulses of 23 nl 
each). Injections were always made on chick 
embryos at E4 (HH23), unless otherwise stated. The 
following molecules were microinjected: bovine 
serum albumin (BSA, Sigma B4287, at 50 mg/ml; 
mw 66 kDa); and ovalbumin (Sigma, A7641, at 50 
mg/ml; mw 44 kDa). Ovalbumin was previously 
labelled with FITC to distinguish it from the 
endogenous one. Ovalbumin-FITC coupling was 
made according to Sigma standard protocol, as 
described in Parvas et al. (2008) [14] (FITC-1 
conjugation Kit, Sigma), and the unbound dye was 
separated by gel filtration. 6-aminonicotinamide (6-
AN, Sigma A68203, at 0.4 μg/μl) was microinjected 
into the brain cavity at different stages of chick 
development, i.e. E3 (HH20), H4 (HH23) and E5 
(HH26). 
Obtaining embryonic fluids 
 Embryonic fluids were obtained as previously 
described [14]. Briefly, for E-CSF, after dissecting 
the embryos out of extraembryonic membranes, a 
glass microneedle (30-μm inner diameter at the tip) 
connected to a microinjector (Nanoject II) was 
carefully placed in the middle of the mesencephalic 
cavity under dissecting microscope control. Then E-
CSF was slowly aspirated, avoiding contact with the 
neuroepithelial wall.  Conversely, E-serum was 
obtained in ovo. After opening a small window in 
the eggshell, the chorioallantoic membrane was 
dissected with a tungsten needle. Then the blood 
was microaspired thought the outflow tract of the 
embryonic heart, and immediately centrifuged to 
remove cells. A minimum of 10 embryos were used 
for each experiment. To minimize protein 
degradation, samples were kept at 4°C during these 
procedures and immediately frozen at -20°C until 
use. 
Detection and quantification of molecules 
from embryonic fluids 
 Slot-blot was used to detect and quantify all 
of the analysed molecules in the embryo fluids as 
described in Parvas et al. (2008) [14]. Briefly, 
embryonic fluids were applied to nitrocellulose 
membrane (Hybond-N) using a microsample 
filtration manifold (Schleicher and Schuell, 
SRC072/0) connected to a vacuum pump. After 
sample application, membranes were dried to fix 
the proteins, and blocked in 5% powdered defatted 
milk in PBT (MTP) for 2 h at room temperature with 
gentle shaking, except for samples containing BSA, 
which were blocked in PBT alone to avoid 
crossreaction. The membrane was then incubated 
with the corresponding primary antibody, which 
was properly diluted in MTP, overnight at 4 °C, 
except for samples containing BSA, in which the 
primary antibody was diluted just in PBT: i.e. 
mouse anti-BSA (Sigma, B2901) at 1/3000; mouse 
anti-FITC (Sigma, F5636) at 1/2500; and rabbit anti-
ovalbumin (Calbiochem, 126705) at 1/1000. 
 After primary antibody incubation, 
membranes were washed with PBT (4×15 min) at 
room temperature, and subsequently incubated 
with the appropriate secondary antibody diluted in 
MTP for 2 h at room temperature: i.e. goat anti-
mouse or alternatively goat anti-rabbit conjugated 
to HRP (Sigma, A0168 and A0545 respectively) at 
1/3000. Finally membranes were washed with PBT 
(4×15 min) at room temperature, and developed 
with 3-3′-diaminobenzidine tetrahydrochloride 
(DAB; 25 mg of DAB in 50 ml of PBS, 1 ml of CoCl2, 
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and 5 μl of H2O2 30% in the dark). The reaction was 
stopped by washing the filters with distilled water 
(×3). The reaction time and sample dilution for 
each molecule was empirically determined to 
obtain the appropriate contrast with no 
background. 
 Finally, the relative concentrations of these 
molecules were calculated using Scion Image 
software on the scanned slot blots, on the basis of 
the highest immunoreaction for each specific 
experiment, expressed as a ratio of the 
concentration, as described in Parvas et al. (2008) 
[14]. 
Immunohistochemistry 
 To detect CAV-1 expression, chick embryos 
at E3 (HH20), E4 (HH23) and E5 (HH26) were 
processed as described in Parvas et al. (2008). They 
were incubated with the corresponding primary 
antibody, rabbit anti-CAV1 (Beckton, C13630) at 
1/500. As secondary antibody anti-rabbit 
conjugated to Alexa-488 at 1/500 (Molecular 
Probes) was used. Immunostained embryos were 
counterstained with phalloidin-TRITC at 1/2000 
(Sigma, P1951) and/or with TOTO-3 at 1/1000 
(Molecular Probes, T3604) in the presence of 1% 
Rnase (Sigma, R6513), as described in Parvas et al. 
(2008) [14].  
 Immunohistochemistry was also used to 
monitor neural differentiation (anti–beta3-tubulin; 
LabVision), apoptosis (anti–active casapse-3; 
Pharmingen) and cell proliferation (anti–
phophohistone-H3, Millipore) in chick embryos at 
E3 (HH20), E4 (HH23) and E5 (HH26) previously 
microinjected with 6-AN, and on control embryos 
microinjected with saline solution. The used 
secondary antibodies were anti-mouse antibody 
conjugated to Alexa-488 or Alexa-546 at 1/500 
(Molecular Probes). Quantitative analyses of beta3-
tubulin– and caspase-3–expressing cells were 
performed by counting the number of 
neuroepithelial cells showing an immunostained 
cytoplasm in 20 microscopic fields of 1,900 μm2, as 
described in Gato et al. (2005) [12]. Likewise, 
phosphohistone-3–expressing cell analysis was 
carried out by counting the number of 
neuroepithelial cells showing an immunostained 
nucleus, as described in Gato et al. (2005) [12]. 
 Photomicrographs were taken using a 
confocal microscope (Olympus) or with a dissecting 
microscope equipped with epifluorescence (Leica 
MZ16F), and were assembled with Photoshop 
software. 
Measuring cephalic cavities 
 Embryos previously microinjected with 6-AN 
as well as control embryos of at an equivalent 
developmental stage were examined for the width 
and height of the mesencephalic cavity under the 
dissecting microscope, as it had previously been 
reported that the increase in E-CSF volume 
parallels the volume of brain cavities [8, 28], thus 
reflecting water influx from the blood to the E-CSF. 
6-AN microinjected embryos (n=50) were 
compared with controls (n=50) microinjected with 
saline solution, using a non-parametric statistical 
method (Mann-Whitney test). 
RESULTS AND DISCUSSION 
Disruption of protein transfer across the 
embryonic blood–CSF barrier 
 To disrupt blood-CSF barrier properties on 
protein transfer, 6-AN was used. 6-AN was 
microinjected into the mesencephalic cavities of 
chick embryos at E4, and relative concentration of 
an endogenous protein in the blood and CSF was 
examined, i.e. ovalbumin, at several different times 
after 6-AN microinjection (20 min, 2 h and 15 h). 
We couldn’t check the relative concentration of 
this protein later than 15 h after 6-AN 
microinjection because the embryos started 
degenerating shortly thereafter, and died 17 h after 
microinjection. This protein was selected as their 
transport across the embryonic blood-CSF barrier 
had been already precisely determined [14].  
 20 min after 6-AN microinjection, 
endogenous ovalbumin, which is known to be 
taken from the egg reservoir and transported to 
the E-CSF via the blood system, was detected 
approximately at the same concentration in the E-
CSF of both 6-AN and control embryos (Fig. 1A). 2 h 
after 6-AN microinjection, endogenous ovalbumin 
was detected at a slightly higher concentration in 
the E-CSF of control embryos than in the E-CSF of 
the 6-AN microinjected ones, although it was not 
statistically significant. Conversely, 15 h after 6-AN 
microinjection, this endogenous molecule was 
significantly detected at a higher concentration in 
the E-CSF of control embryos than in the 6-AN 
microinjected ones (Fig. 1A), suggesting that the 
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transport of proteins from the blood to the E-CSF is 
at least partially blocked by the use of 6-AN, and 
that the blockage starts to be effective between 2 
to 15 h after 6-AN microinjection. A parallel 
dynamics was observed with respect to ovalbumin 
concentration in the E-serum (Fig. 1A). 
 
 
Figure 1. Bar charts showing disruption of protein transfer across the embryonic blood- CSF barrier after 6-AN 
microinjection into the cephalic cavities at E4. A) Endogenous ovoalbumin; B) Ovoalbumin-FITC; C) BSA. Vertical bars 
indicate SD, and asterisks denote values that differ significantly (P < 0.05) from controls according to the two-tailed 
Student’s t-test. 
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 To further test the extent of the disruption of 
protein transport across the embryonic blood-CSF 
barrier, we then checked the transfer dynamics of 
exogenous microinjected proteins after 6-AN 
treatment. Two different categories of proteins 
were used: (1) a protein that is normally present in 
the E-CSF and the E-serum of chick embryos at this 
stage of development, i.e. ovalbumin, which was 
previously coupled to FITC in order to distinguish it 
from the endogenous one; and (2) a protein that is 
not present in chick embryos (heterologous 
protein), i.e. BSA. These proteins were selected as 
their transport across the embryonic blood-CSF 
barrier had been already precisely determined [14]. 
In this respect, it has been reported that ovalbumin 
is quickly transported from the blood to the E-CSF 
when exogenously microinjected into the outflow 
of the heart, and thus it was used in this 
experiment as ovalbumin-FITC to monitor the 
blockage of protein transport from the blood to the 
E-CSF. Conversely, it is known BSA not to be 
transported from the blood to the E-CSF when 
microinjected into the outflow of the heart, but it is 
quickly remove from the E-CSF when microinjected 
into the brain cavity. Thus, in this experiment it was 
microinjected into the brain cavity to check the 
blockage of protein transport from the E-CSF to the 
E-serum. 
Ovalbumin-FITC was microinjected into the outflow 
of the heart of 6-AN treated embryos at three 
different times after 6-AN microinjection: just 
immediately thereafter; 2h after 6-AN 
microinjection; and 15 h after 6-AN microinjection. 
In all experiments, E-CSF and E-serum were 
removed 20 minutes after ovalbumin-FITC 
microinjection. In this way, we were able to check 
the blockage of protein transfer after different 
times of 6-AN treatment. As a control, we used 
embryos that were microinjected with 
Ovoalbumin-FITC into the outflow of the heart but 
no-treated with 6-AN. 
 20 min and 2 h after 6-AN microinjection, 
ovalbumin-FITC was detected approximately at the 
same concentration in the E-CSF of both 6-AN and 
control embryos. However, at 15 h, the relative 
concentration of this molecule in the E-CSF of 
control embryos was 2-folds higher than in 6-AN 
treated embryos. Conversely, with respect to E-
serum, the relative concentration of ovalbumin-
FITC was 2- to 3-folds higher in the 6-AN treated 
embryos with respect to control ones (Fig. 1B). 
Taken together, these results suggest that the 
transport of proteins from the blood to the E-CSF is 
at least partially blocked by the use of 6-AN, and 
that the blockage starts to be effective between 2 
to 15 h after 6-AN microinjection. 
 
Figure 2. Immunohistochemical expression of CAV1 in microinjected chick embryos at E4 with 6-AN and control 
embryos (non-microinjected embryos). Merged confocal image (50 µm thick) of 200-µm vibratome sections. Note the 
CAV-1 immunoreactive blood vessels in control embryos (in green). Arrows point to blood vessels. Note than in 6-AN 
treated embryos CAV-1 expression is not detected. Cellular counterstaining is shown in red. Scale bars: 0.1 mm; 
Abbreviations: bc, brain cavity; m, mesechyme; n, neuroectoderm. 
 With respect to BSA, it was microinjected 
into the brain cavity of embryos to which 6-AN had 
been previously microinjected 20 min, 2 h and 15 h 
after 6-AN microinjection. As a control, we used 
embryos that were microinjected with BSA into the 
mesencephalic cavities but no-treated with 6-AN. 
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In this experiment, BSA removal from the cephalic 
cavities of 6-AN treated embryos were 
progressively restricted with time, from 2 to 15 h 
after 6-AN microinjection, as revealed by the 
increasingly accumulation of this molecule with 
respect to controls (2-folds after 20 min and 2 h, 
and 6- to 7-folds after 15 h). With respect to E-
serum, again no significant differences between 6-
AN treated embryos and controls were observed 
after 20 min and 2 h, but after 15 h the 
accumulation of BSA in the E-serum was significant 
(Fig. 1C). Taken together, these results also suggest 
that the transport of proteins from the blood to the 
E-CSF is at least partially blocked by the use of 6-
AN, and that the blockage is increasingly effective 
with time. 
 
Figure 3. Neurogenesis, cell survival and cell proliferation in chick embryos at E4, E5 and E6, embryos microinjected 
with 6-AN and non-microinjected embryos. Beta3-tubulin immunostaining was used to evaluate neural differentiation. 
Active caspase-3 immunostaining was used to examine cell survival. Phosphohistone-H3 immunostaining was used to 
analyze cell proliferation. 
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Figure 4. Plots showing quantification of the mentioned parameters of cell behavior. Results are expressed as mean 6 
SD of three individual experiments per group. Vertical bars indicate SD, and asterisks denote values that differ 
significantly (P < 0.05) from controls according to the two-tailed Student’s t-test. 
 Finally, we checked the cause of protein 
transport blockage. In this respect, as it had been 
suggested that protein transfer from the blood to 
E-CSF and vice versa is mediated by CAV-1 
containing caveolae [16], we analysed whether 
protein transfer disruption induced by 6-AN 
treatment was due to an impairment of 
transcellular caveolae transport by monitoring 
CAV-1 expression in 6-AN treated embryos 15 h 
after microinjection with respect to controls. As 
shown in Fig. 2, CAV-1 is no longer expressed in 
treated embryos, as compared with controls. Taken 
together, these results indicate that protein 
transport across the blood-CSF barrier is disrupted 
by 6-AN treatment, and that this disruption is due, 
at least in part, to the interruption of transcellular 
caveolae transport, as detected by CAV-1 
expression cease. 
Disruption of protein transport affects 
neuroectodermal progenitor cells survival, 
proliferation and neurogenesis  
 As 6-AN can block the transport of proteins 
between E-serum and E-CSF and vice versa, and 
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molecules contained within E-CSF are involved in 
neuroectodermal progenitor cells survival, 
proliferation and neurogenesis in vitro [12], we 
then check whether these basic cellular parameters 
were also altered in 6-AN treated embryos, due to 
the lack of protein transport. To check this extent, 
chick embryos at several different developmental 
stages, i.e. E3 (HH20), E4 (HH23) and E5 (HH26), 
were microinjected with 6-AN, and examined for 
these basic parameters 15 h thereafter with 
respect to controls. 
 At E3, no significant differences in any of the 
parameters analysed were observed between 6-AN 
microinjected embryos and controls (Fig. 3 and 4), 
which is in agreement with the fact that at this 
developmental stage the blood-CSF barrier is still 
underdeveloped, as previously reported by Parvas 
et al. (2008) [14]. However, at E4, when this 
transient embryonic blood-CSF barrier is functional, 
cell proliferation and neurogenesis is significantly 
reduced in 6-AN treated embryos with respect to 
controls, and apoptosis is significantly increased 
(Figures 3 and 4). Finally, at E5 embryos, cell 
proliferation and neurogenesis is also significantly 
reduced in 6-AN treated embryos with respect to 
controls, and apoptosis is significantly increased, 
but differences are smaller than in E4 embryos. 
 Taken together, these results indicate that 
protein transport blockage is affecting the basic 
cellular parameters of neuroepithelial progenitor 
cell from the developmental stage at which the 
embryonic blood-CSF barrier is active, i.e. E4, but 
not before that, which in turn reflects the 
importance of this barrier for normal early brain 
development. In this respect, the alteration of the 
normal cellular basic parameters can be due to the 
lack of certain factors that should normally be in 
the E-CSF, and/or to the presence of cellular 
metabolites within the E-CSF, that can not be 
removed from this fluid and that can exert some 
toxic effects. 
 
 
Figure 5. Comparison between an embryo treated with 6-AN to block transport across the blood–CSF barrier and a 
control embryo. Lines show the width and height of the mesencephalic vesicles. Also note that the telencephalic 
vesicles appear smaller in the treated embryo with respect to the control. Scale bar: 0.5 mm. Abbreviations: h, height 
of the mesencephalon; t, telencephalon; w, width of the mesencephalon. 
Disruption of water transport across the 
embryonic blood–CSF barrier 
 Finally, we also checked whether the 
blockage of transcellular caveolae transport 
induced by 6-AN also affects water transport from 
the blood to the E-CSF, as it has been previously 
suggested that water uses caveolae to cross the 
neuroectodermal cells fulfilling blood-CSF barrier 
function [16]. Fifteen hours after 6-AN 
microinjection to E4 embryos, they were examined 
for the width and height of the mesencephalic 
cavity under the dissecting microscope (Fig. 5), as it 
had been reported that the increase in E-CSF 
volume parallels that of the brain cavities. 
Interestingly, mesencephalic cavities of 6-AN 
treated embryos were clearly smaller than those of 
controls. Other cavities, for example telencephalic 
cavities, were also smaller in treated embryos, 
although they were not quantified (Fig. 5). 
 We then studied the normal distribution of 
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the values. We first used the chi-square test of 
normality. The values obtained for the width 
variable were as follows: 6-AN treated embryos, 
chi-square = 84.64 and p-value = 9.8046 x 10-12; 
control embryos, chi-square = 166.72 and p-value = 
0.0. The values obtained for the height variable 
were as follows: 6-AN treated embryos, chi-square 
= 83.92 and p-value = 1.33136 x 10-11; control 
embryos, chi-square = 137.92 and p-value = 0.0. 
Thus, the samples did not follow a normal 
distribution. 
 For this reason, we then used a non-
parametric test to compare our variables (Mann-
Whitney test; void hypothesis: both 6-AN treated 
embryos and controls follow the same distribution 
and thus they have the same mean and variance). 
The values obtained for the width variable were as 
follows: U = 603.5; p-value = 0.000008. The values 
obtained for the height variable were as follows: U 
= 211.0; p-value = 0.00. Thus, in both cases there 
were significant differences between 6-AN treated 
embryos and controls, indicating that 
mesencephalic expansion in 6-AN treated embryos 
is significantly lower than in controls. 
 So the disruption of the embryonic barrier 
produces a significant reduction in the volume of 
the mesencephalic vesicle, which, according to the 
literature, may be the consequence of a decrease 
in brain cavity hydrostatic pressure [11], and thus 
to a decrease in the water imbalance from the 
blood to the E-CSF. Taken together, these results 
indicate that the barrier function of the blood 
vessels and the neuroectoderm adjacent to them is 
not restricted to proteins, but that it also includes 
other molecules such as water and most possible 
also ions. These observations reinforce the 
hypothesis that these embryonic blood vessels and 
the neuroectoderm adjacent to them have a 
transient blood–CSF barrier function during early 
stages of brain development, before the formation 
of the functional choroid plexus, which appears 
later in development. Consequently, they are 
crucial for brain anlagen growth and differentiation 
as they modulate E-CSF composition and 
homeostasis. 
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